Delivra Health Brands (DHB) AI Stock Analysis

• Market Cap: C$5.31M
• Dividend Yield: N/A
• Average Volume (3M): 7.56K
• Price to Earnings (P/E): 181.8
• Beta (1Y): -0.63
• Revenue Growth: 10.39%
• EPS Growth: 99.07%
• Country: CA
• Employees: 22
• Sector: General
• Sector Strength: N/A
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 0.00
• Shares Outstanding: 31,261,782
• 10 Day Avg. Volume: 1,759
• 30 Day Avg. Volume: 7,556
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 0.00
• Price to Cash Flow (P/CF): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: C$0.73
• Price Target Upside: 329.41% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

Delivra Health Brands is showing strong revenue growth and improved cash flow, but challenges remain with profitability and financial valuations. Technical indicators are mixed, indicating uncertainty in market momentum. Recent corporate events are positive, potentially supporting future growth.

Delivra Health Brands Business Overview & Revenue Model

Company Description

Delivra Health Brands (DHB) operates within the health and wellness sector, focusing on the development and commercialization of innovative delivery systems for active ingredients. The company specializes in creating topical and transdermal formulations designed to enhance the absorption and efficacy of various compounds. DHB's core products include a range of creams, gels, and other topical solutions aimed at addressing pain management, skincare, and other health-related concerns.

How the Company Makes Money

Delivra Health Brands generates revenue primarily through the sale of its proprietary topical and transdermal products. The company markets these products directly to consumers as well as through partnerships with retailers and distributors in the health and wellness industry. In addition to direct product sales, DHB may also engage in licensing agreements, allowing other companies to utilize its patented delivery technologies in their own product lines. Significant partnerships with healthcare providers or retail chains can amplify distribution and sales, further contributing to the company's earnings. Additionally, the company may invest in research and development to continue innovating and expanding its product offerings, which can lead to new revenue streams.

Delivra Health Brands Financial Statement Overview

Summary

Delivra Health Brands is experiencing positive revenue growth and improved gross profit margins, indicating better cost management. The balance sheet shows stable equity levels and manageable debt. Cash flows have improved, showing strong cash generation. However, persistent negative EBIT margins and low net profitability remain concerns.

Income Statement

Delivra Health Brands has shown positive trends in revenue growth, with an increase from $9.79M in 2023 to $12.57M in TTM, resulting in a 28.4% growth rate. The gross profit margin has improved significantly to 47.2% in TTM, indicating better cost management. However, the company is struggling with negative EBIT margins and thin net profit margins, which could be a concern for long-term profitability.

Balance Sheet

The balance sheet shows a relatively stable equity base with a debt-to-equity ratio of 0.50 in TTM, indicating modest leverage. The equity ratio stands at 50.9%, showing solid equity financing. However, the return on equity is minimal at 0.14%, reflecting the challenge in generating returns from equity capital.

Cash Flow

The cash flow statement highlights a positive trend in free cash flow, which increased from negative values to $407K in TTM. The operating cash flow to net income ratio is high, indicating strong cash generation relative to reported profits. The company needs to maintain this momentum to ensure liquidity and operational flexibility.

Breakdown
Jun 2024	Jun 2023	Jun 2022	Jun 2021	Jun 2020
Income Statement		Total Revenue
12.38M	9.79M	8.14M	7.96M	7.78M
	Gross Profit
6.40M	3.49M	485.00K	-297.00K	-1.62M
	EBIT
-710.00K	-1.36M	-6.01M	-9.26M	-15.69M
	EBITDA
2.35M	1.40M	-4.25M	-7.04M	-55.40M
	Net Income Common Stockholders
876.00K	-184.00K	-7.01M	-28.54M	-79.86M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
4.20M	2.73M	1.11M	5.14M	1.41M
	Total Assets
10.05M	10.56M	11.59M	19.06M	57.84M
	Total Debt
2.03M	1.96M	2.11M	2.16M	5.97M
	Net Debt
-2.17M	-764.00K	1.02M	-2.27M	4.57M
	Total Liabilities
4.86M	7.17M	8.21M	9.09M	21.27M
	Stockholders Equity
5.19M	3.39M	3.37M	9.98M	33.52M
Cash Flow		Free Cash Flow
756.00K	-1.13M	-4.46M	-9.68M	-24.67M
	Operating Cash Flow
756.00K	-1.09M	-4.44M	-9.65M	-18.36M
	Investing Cash Flow
11.00K	2.91M	1.35M	12.27M	-3.64M
	Financing Cash Flow
594.00K	-255.00K	-309.00K	446.00K	3.17M

Delivra Health Brands Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 0.17
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:DHB, the sentiment is Neutral. The current price of 0.17 is above the 20-day moving average (MA) of 0.17, below the 50-day MA of 0.17, and below the 200-day MA of 0.20, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 49.61 is Neutral, neither overbought nor oversold. The STOCH value of 43.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for TSE:DHB.

Delivra Health Brands Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CRON	67 Neutral	$982.82M	17.18	3.80%	―	35.87%	―
DHB	58 Neutral	C$5.31M	181.82	0.15%	―	10.39%	99.07%
Sector *	56 Neutral	$4.37B	5.27	-19.28%	5.13%	19.96%	-54.67%
OGI	53 Neutral	$200.75M	―	-18.27%	―	7.33%	84.41%
ACB	50 Neutral	$367.17M	28.77	4.78%	―	16.39%	-98.10%
WEED	47 Neutral	$335.02M	―	-84.50%	―	-16.27%	―
TLRY	44 Neutral	$459.28M	―	-31.06%	―	11.22%	-108.58%

Delivra Health Brands Corporate Events

Delivra Health Expands Dream Water® Line with New Sleep Gummies in Canada

Delivra Health Brands has announced the launch of its new 6-Count Sleep Gummies under the Dream Water® brand in the Canadian market, following the success of its 60-count version. This strategic launch aims to capture growth opportunities in travel and convenience retail channels, enhancing the company’s market position as a leading provider of sleep solutions. The new product will be distributed nationwide through established retail and e-commerce partners, potentially strengthening Delivra Health’s presence in both Canadian and US markets.

Delivra Health Brands Reports 34% Revenue Growth in Q2 Fiscal 2025

Delivra Health Brands Inc. reported a 34% increase in net revenue for the second quarter of fiscal 2025 compared to the same period last year, driven by higher sales of Dream Water® in the U.S. and Canada. The company has significantly increased its marketing investments to boost brand awareness and remains on track to meet its commercial and financial goals for the fiscal year. Despite a rise in expenses due to marketing efforts, the company continues to focus on long-term growth through expanding its customer base and launching new initiatives.

Delivra Health Brands to Announce Q2 Fiscal 2025 Results and Host Conference Call

Delivra Health Brands Inc. announced it will release its financial results for the second quarter of fiscal 2025 on February 27, 2025, and will host a conference call to discuss these results. This announcement is significant for stakeholders as it provides an opportunity to gain insights into the company’s financial performance and strategic direction, potentially impacting its market positioning in the health and wellness industry.

Delivra Health Brands to Implement 10-to-1 Share Consolidation

Delivra Health Brands Inc. announced it will consolidate its common shares on a 10-to-1 basis, effective February 21, 2025, reducing the number of issued and outstanding common shares significantly. This move is expected to streamline the company’s share structure without changing its name, and it involves adjustments to existing stock options and warrants, potentially impacting stakeholder holdings.